Last updated: July 27, 2026
Executive summary
Alza Corp. v. Amneal Pharmaceuticals of New York, LLC (N.D. Ill., No. 1:16-cv-00914) is a patent-infringement case tied to Amneal’s FDA generic submission for a branded drug associated with ALZA’s drug-delivery IP. The record in this matter is not provided here (docket text, complaint, asserted patents, claim construction, infringement contentions, final judgment, and any settlement terms). Without those case-specific inputs, a complete litigation summary and infringement/validity analysis cannot be produced accurately.
Alza Corporation v. Amneal 1:16-cv-00914: what patents were asserted and what were the key claims?
No complete, accurate answer can be produced.
Which ALZA patents were listed in the complaint?
Not available.
What product/dosage form and delivery mechanism were at issue?
Not available.
What theory did ALZA plead (infringement of drug, method of use, formulation, manufacturing, or composition claims)?
Not available.
What happened procedurally in Alza v. Amneal (N.D. Ill. 1:16-cv-00914)?
No complete, accurate answer can be produced.
What were the initial motion rulings (12(b)(6), transfer/venue, preliminary injunction)?
Not available.
Were there claim construction and Markman proceedings?
Not available.
What did the infringement contentions require Amneal to answer?
Not available.
How did the court analyze infringement in Alza Corp. v. Amneal?
No complete, accurate answer can be produced.
What claim elements were contested?
Not available.
Was infringement decided on summary judgment or trial?
Not available.
Did the court narrow claims via construction?
Not available.
How did the court analyze invalidity (anticipation, obviousness, indefiniteness, written description) in Alza v. Amneal?
No complete, accurate answer can be produced.
Which prior art references were used?
Not available.
Was there a PTAB interplay (post-grant reviews/inter partes reviews) affecting the case?
Not available.
Which statutory grounds did Amneal use?
Not available.
What was the outcome of Alza v. Amneal 1:16-cv-00914?
No complete, accurate answer can be produced.
Did ALZA win a final judgment?
Not available.
Did the case terminate by dismissal, consent judgment, or settlement?
Not available.
Were there attorneys’ fees or costs awarded?
Not available.
Did the case involve Hatch-Waxman paragraph IV certifications and what was the FDA exclusivity timing impact?
No complete, accurate answer can be produced.
Which FDA application and product label were implicated?
Not available.
What was the Paragraph IV posture (notice, timing, regulatory stay, forfeiture risks)?
Not available.
Did the litigation align to a generic approval or a tentative approval timeline?
Not available.
What settlement terms affected market entry for Amneal and other generics?
No complete, accurate answer can be produced.
Was there a license, co-existence agreement, or paid-upfront settlement?
Not available.
Were there market carve-outs, supply limitations, or launch dates?
Not available.
Did any other firms get pulled into the resolution?
Not available.
How strong is the ALZA patent estate implied by this litigation (strength, coverage, enforceability)?
No complete, accurate answer can be produced.
Were the asserted patents composition, formulation, or delivery-system claims?
Not available.
Were there multiple families and overlapping priority dates?
Not available.
Were any patents found not infringed or invalid?
Not available.
How does Amneal’s generic risk profile change based on the litigation posture in 1:16-cv-00914?
No complete, accurate answer can be produced.
What remaining patents would typically survive if some claims failed?
Not available.
What design-around options were available (different polymers, layers, membranes, release profiles)?
Not available.
Did the case create precedent on ALZA’s drug-delivery claim scope?
Not available.
Key Takeaways
No litigation-specific conclusions can be provided without the asserted-patent record and case disposition.
FAQs
-
What patents were asserted in Alza Corp. v. Amneal (1:16-cv-00914)?
Not available.
-
Did Alza v. Amneal result in an injunction or a final finding of infringement?
Not available.
-
What was the court’s claim construction in Alza v. Amneal?
Not available.
-
Did Amneal challenge the asserted patents for obviousness or anticipation using specific prior art?
Not available.
-
How did the case affect FDA approval and generic launch timing?
Not available.
References
No sources were provided in the prompt.
